A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Leukemia and Lymphoma

• Publication date

  2015-01-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/10428194.2015.1010078PMID 25629994
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

  2017cited by this paper
• An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.

  2014cited by this paper
• Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era

  2014cited by this paper
• Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study

  2014cited by this paper
• Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study

  2013cited by this paper
• Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement.

  2013cited by this paper
• Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: a meta-analysis

  2012cited by this paper
• The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.

  2012cited by this paper
• High Ki67 Index and Bulky Disease Remain Significant Adverse Prognostic Factors in Patients with Diffuse Large B Cell Lymphoma before and after the Introduction of Rituximab

  2011cited by this paper
• Bulky disease has an impact on outcomes in primary diffuse large B‐cell lymphoma of the breast: a retrospective analysis at a single institution

  2011cited by this paper
• Male gender is an adverse prognostic factor in B‐cell lymphoma patients treated with immunochemotherapy *

  2011cited by this paper
• Primary gastric diffuse large B‐cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG‐PET scan

  2010cited by this paper
• Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B‐cell lymphoma treated with R‐CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E‐IPI)

  2010cited by this paper
• Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy.

  2010cited by this paper
• Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas

  2010cited by this paper
• Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

  2010cited by this paper
• Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B‐cell lymphoma

  2009cited by this paper
• Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab

  2008cited by this paper
• Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B‐cell lymphoma and suggests patients’ survival benefit from rituximab

  2008cited by this paper
• Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas

  2008cited by this paper
• Absolute lymphocyte count is a prognostic factor in diffuse large B‐cell lymphoma

  2008cited by this paper
• The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma—a population-based study

  2007cited by this paper
• The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.

  2007cited by this paper
• Diffuse large B-cell lymphoma.

  2007cited by this paper
• Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma

  2007cited by this paper
• Absolute lymphocyte count predicts overall survival in follicular lymphomas

  2006cited by this paper
• Clinical Trials and Observations

  2005cited by this paper
• Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors

  2005cited by this paper
• large B-cell lymphoma

  2005cited by this paper
• Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation

  2004cited by this paper
• Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

  2004cited by this paper
• Parental longevity and prognosis in elderly patients with aggressive non-hodgkin's lymphoma

  2004cited by this paper
• CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

  2002cited by this paper
• CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

  2002cited by this paper
• Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi.

  2000cited by this paper
• A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

  1998cited by this paper
• A predictive model for aggressive non-Hodgkin's lymphoma.

  1993cited by this paper
• The Role of Sex

  1990cited by this paper
• Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival

  1989cited by this paper
• A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels.

  1989cited by this paper
• A Comparison of

  1971cited by this paper
• THE WORLD HEALTH ORGANIZATION

  1954cited by this paper
• Hodgkin’s Disease

  1933cited by this paper

• Older patients with lymphoma: navigating a landscape of clinical controversies and barriers to innovation.

  2026cites this paper
• The prognostic value of the tumor metabolic volume in predicting the response to therapy in patients with diffuse large B-cell lymphoma

  2025cites this paper
• Retrospective analysis of diffuse large B-cell lymphoma treated with the R-CHOP regimen at a Malaysian tertiary hospital

  2025cites this paper
• Validation of US Consensus Eligibility Criteria for Front‐Line DLBCL Trials

  2025cites this paper
• International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma.

  2025cites this paper
• Tumor Microenvironment, Inflammation, and Inflammatory Prognostic Indices in Diffuse Large B-Cell Lymphomas: A Narrative Review

  2025cites this paper
• A Real‐World Data‐Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B‐Cell Lymphoma Patients

  2024cites this paper
• Validation of prognostic models in elderly patients with diffuse large B-cell lymphoma in a real-world nationwide population-based study – development of a clinical nomogram

  2024influential citation
• Revisiting beta‐2 microglobulin as a prognostic marker in diffuse large B‐cell lymphoma

  2024cites this paper
• Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models

  2023cites this paper
• Association between serum albumin levels and survival in elderly patients with diffuse large B-cell lymphoma: a single-center retrospective study

  2023influential citation
• Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study

  2022cites this paper
• Impact of C-reactive protein and albumin levels on short, medium, and long term mortality in patients with diffuse large B-cell lymphoma

  2022influential citation
• Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index

  2022cites this paper
• Clinical Characteristics, Outcomes, and Risk Factors for Patients with Diffuse Large B-Cell Lymphoma and Development of Nomogram to Identify High-Risk Patients

  2022cites this paper
• CLEP_A_244294 537..555

  2020influential citation
• Diffuse Large B-Cell Lymphomas in Older Adults

  2020cites this paper
• Statistical Challenges in Development of Prognostic Models in Diffuse Large B-Cell Lymphoma: Comparison Between Existing Models – A Systematic Review

  2020cites this paper
• Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma

  2019cites this paper
• Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma - Use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: A Humedica database retrospective cohort analysis, 2007-2015.

  2019cites this paper
• Analysis Results of the Regional Registry of Patients with Diffuse Large B-cell Lymphoma: Risk Factors and Chemo-Immunotherapy Issues

  2019cites this paper
• Available prognostic models for risk stratification of diffuse large B cell lymphoma patients: a systematic review.

  2019cites this paper
• Syddansk Universitet Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma a critical assessment of the R-IPI , IPI , and NCCN -

  2018cites this paper
• Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by Use of Machine Learning and Nationwide Lymphoma Registries: A Nordic Lymphoma Group Study.

  2018cites this paper
• Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma a critical assessment of the R-IPI, IPI, and NCCN-IPI

  2018cites this paper
• The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries

  2017cites this paper
• Validation of the NCCN‐IPI for diffuse large B‐cell lymphoma (DLBCL): the addition of β2‐microglobulin yields a more accurate GELTAMO‐IPI

  2017cites this paper
• Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.

  2017cites this paper
• Simplicity at the cost of predictive accuracy in diffuse large B‐cell lymphoma: a critical assessment of the R‐IPI, IPI, and NCCN‐IPI

  2017cites this paper
• Serum albumin level at diagnosis of diffuse large B‐cell lymphoma: an important simple prognostic factor

  2016cites this paper
• Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.

  2015cites this paper
• Is 70 the new 60? New international prognostic index with an older age cut-off for diffuse large B-cell lymphoma

  2015cites this paper
• Prognostic clinical and serum biomarkers in diffuse large B-cell lymphoma.

  year unknowncites this paper